Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Assess the Safety and Efficacy of DBd Combination Therapy (DOXIL/CAELYX) [Doxorubicin HCL Liposome Injection], VELCADE [Bortezomib] and Dexamethasone) for Previously Untreated Multiple Myeloma Patients

NCT00561743 is registered in ClinicalTrials.gov with Janssen-Ortho Inc., Canada as lead sponsor.

NCT NCT00561743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00561743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Assess the Safety and Efficacy of DBd Combination Therapy (DOXIL/CAELYX) [Doxorubicin HCL Liposome Injection], VELCADE [Bortezomib] and Dexamethasone) for Previously Untreated Multiple Myeloma Patients
Lead sponsor
Janssen-Ortho Inc., Canada
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
May 31, 2007
Enrollment
50 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma